BSP – Biological Signal Processing Ltd.

BSP is dedicated to providing novel, non-invasive and highly reliable solutions for the diagnosis and monitoring of Ischemic Heart Disease.

Using proprietary signal processing technology,  BSP’s products perform analysis of the high-frequency QRS components for more sensitive and accurate results than conventional stress testing and recently, also for resting ECG tests. The short video below describes this exciting technology.

Integration of BSP’s innovative technology into top-of-the-line stress ECG systems enables a unique solution providing superior diagnostic accuracy, while utilizing conventional stress testing protocols.

What’s New
The HyperQ Rest system obtains FDA approval - the first product using the Resting ECG technology with 510(k) approval
BSP receives notice of allowance from the USPTO for a patent regarding its high frequency ECG technology for indicating ischemia
Office of the Chief Scientist (OCS) approves funding for continuing the development of the Resting ECG technology
BSP presented its study on continuous HyperQ monitoring at the 12th International Dead Sea Symposium (IDSS)
BSP receives notice of allowance from the USPTO for a patent regarding its signal processing technology
BSP's latest patent covering HyperQ for resting ECG receives notice of allowance from USPTO
BSP and Schiller launch the HyperQ Analyzer Rest at the ESC congress in Amsterdam
BSP receives notice of allowance from the USPTO for its patent on identification of myocardial ischemia
BSP receives CE certificate for its first product in the Resting ECG product line